San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
As November 2025 unfolds, the global stock markets find themselves at a critical juncture, struggling to reclaim the robust bullish momentum that characterized much of the preceding years. A palpable shift in investor sentiment is emerging, with an increasing number of market participants questioning the lofty valuations, particularly within the
Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.67 per share was 8.5% above analysts’ consensus estimates.
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in turn, significantly bolstered the US Dollar, pushing it to multi-month highs against a basket of major currencies. The immediate implication for
The financial markets, still reeling from a tumultuous period marked by significant downturns, are now grappling with an uneasy attempt at consolidation. As of November 5, 2025, investors are witnessing a landscape fundamentally altered by a series of sharp slides, most notably the tariff-induced crash of April 2025 and a
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo Nordisk (NYSE: NVO), a pioneer in the space with its blockbuster drugs Wegovy and Ozempic, has experienced a tumultuous year, seeing
The United States finds itself in an unprecedented economic fog as a prolonged government shutdown, now stretching well into its second month, has brought the flow of critical official data to a grinding halt. With federal agencies responsible for collecting and disseminating vital economic indicators largely shuttered, policymakers, businesses, and
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
Washington D.C., November 5, 2025 – The United States is grappling with an unprecedented fiscal crisis, as an ongoing government shutdown, now in its 36th day, has officially become the longest in the nation's history. This prolonged political impasse, rooted in fierce partisan disagreements over federal spending and policy riders,
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.
The financial world is holding its breath as the release of the upcoming U.S. Purchasing Managers' Index (PMI) data draws near. This crucial economic indicator is not merely a snapshot of business activity; it's a powerful barometer of the nation's economic health, capable of sending significant ripple effects through
As of November 4, 2025, the global financial markets are witnessing a significant shift, with a rallying US dollar and a retreating stock market exerting considerable downward pressure on gold and silver prices. This confluence of macroeconomic factors, primarily driven by a hawkish outlook on interest rates, is creating a
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
